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Osteopathology of the jaw associated with bone
resorption inhibitors: what have we learned in the
last 8 years?
A single-centre experience with 110 patients
Christine Jacobsen, Philipp Metzler, Joachim Anton Obwegeser, Wolfgang Zemann, Klaus Wilhelm Graetz
Department of Craniomaxillofacial Surgery, University Hospital of Zurich, Switzerland
Summary
QUESTIONS UNDER STUDY: 8 years after discovery of
osteonecrosis of the jaw associated with bisphosphonate ther-
apy a lot of experience has been garnered in treating 112 pa-
tients with this disease. This disease, although uncommon, is
still a burden for the patient as well as the treating specialists
and an adequate standardised classification as well as therapy
does not exist. This article presents a summary of collected
patient data, garnered experience and consequential changes
in knowledge, in diagnostic measures and therapy.
METHODS: The data of in total 112 patients referred to the
Special Clinics for patients with bisphosphonate-associated
lesions of the jaw was retrospectively analysed and com-
pared with data from the literature.
RESULTS: In total, 110 patients, 70% women, were in-
cluded in the data analysis. A quarter of those patients had
osteoporosis as the underlying disease, more than half of all
patients had extractions as the local influencing factor. The
lesion was localised in the mandible in three quarters of all
patients and almost all patients showed clinical signs of in-
fection. In total, 58% of all patients were treated surgically
with a complete remission rate of 78% over 7 years.
CONCLUSIONS: This summary of patient data and literat-
ure shows that knowledge about bisphosphonate-associated
osteopathology of the jaw becomes more and more specific.
The range of drugs associated with this disease has increased,
but also therapeutic options show more and more success.
Classifications, published shortly after the discovery of
BRONJ need to be revised and new knowledge included.
Key words: bone resorption inhibitors; osteopatholgy;
local risk factor; infection
Introduction
In 2006, 3 years after the “discovery” of a jaw-affecting
disease associated with bisphosphonate therapy, this journ-
al published a report of clinical experiences with
bisphosphonate-associated osteonecrosis of the jaw
(BRONJ) [1]. BRONJ has been described as a type of os-
teonecrosis of the jaws that occurs more often in the mand-
ible than the maxilla. The first publication was presented
by Robert Marx, who described BRONJ as a rediscovery
of a similar disease called “phosphorous necrosis,” which
occurred in match-factory workers in the 19th century.
However, the exact pathophysiology of BRONJ is not yet
established. Hence, different hypotheses about its patholo-
gical mechanism have been offered, e.g., avascular necros-
is, suppression of bone remodelling, and direct toxicity of
bisphosphonates on bone and soft tissue [2, 3].
Different factors, including the cumulative dosage of bi-
sphosphonate, underlying diseases, and locally invasive
dental therapy, have been identified as risk factors for the
occurrence of this multifactorial disease. Soon after
presentation of BRONJ, treatment with complete remission
was determined to be difficult or nearly impossible, and
prevention noted as essential.
A definition and staging system of BRONJ was presented
in 2007 and updated in 2009 by the American Association
of Oral and Maxillofacial Surgeons (AAOMFS) and has
been widely used to date [4]. According to this publication,
BRONJ is defined by the following three criteria:
1. Current or previous treatment with bisphosphonates
(BPs),
2. Exposed bone for more than 8 weeks, and
3. No history of radiation therapy.
The staging system ranges from stage 0: “absence of nec-
rotic bone, but presence of nonspecific clinical findings and
symptoms” (which conflicts with criterion 2 of the defini-
tion provided by the AAOMFS) to stage 3: “presence of ex-
posed, necrotic bone with signs of infection extending bey-
ond the border of the alveolar bone region” [4].
Eight years after the first publication, a lot of experience
has been garnered on this disease. Moreover, information
from other clinicians and our own treatment of a large num-
ber of patients have led to a clearer clinical picture, better
diagnosis, and a change in treatment strategies for BRONJ.
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Several aspects of the definition and staging system of the
AAOMFS have come into question, and the need for revi-
sion is obvious, as stated by Colella et al. [5].
One example is the introduction of new drugs to the market
that inhibit bone resorption, such as the RANK ligand in-
hibitors Xgeva® and Prolia® (denosumab; Amgen, Zug,
Switzerland). These drugs have led to promising results in
various studies, but also to osteopathology of the jaw as a
side effect [6–8]. This fact stands in contrast to the first cri-
terion of the AAOMS definition of BRONJ.
The aim of this article is to provide an update on current
knowledge regarding jaw-associated side effects of treat-
ment with BPs and other bone resorption inhibitors. An
up-to-date overview of epidemiology, risk factors, clinical
signs, possible diagnostic methods, and treatment strategies
will be presented, based on an analysis of relevant literature
and our own clinical experience with 112 patients.
Material and methods
In the last 7 years, 112 patients with osteonecrosis of the
jaw (ONJ) associated with bone resorption–inhibiting
drugs, such as BPs and receptor activator of nuclear factor
kappa-B ligand (RANKL) inhibitors, have been referred to
the Department of Craniomaxillofacial Surgery, University
Hospital of Zurich, by dentists or different specialists deal-
ing with bone resorption-inhibition therapy. All patients
were diagnosed, treated, and followed in an osteonecrosis
outpatient clinic. Retrospective data collected included age,
gender, and medical history of all patients, as well as type
and duration of BP medication.
All patients were examined clinically, and different types
of imaging were performed depending on the individual
situation of each patient. In most patients, panoramic X-
rays were taken to assess the dental situation and necessary
preventative measures. Additional diagnostic imaging,
such as computed tomography (CT), magnetic resonance
imaging (MRI), or cone-beam CT, was performed to assess
the extent of the lesion and the involvement of other struc-
tures. Additionally, in most patients with a history of malig-
nancy, a bone biopsy was performed to exclude metastases
of the underlying disease.
Depending on the individual situation, underlying disease,
and general health status, different therapeutic measures
were implemented, ranging from conservative treatment
in patients with poor general condition to wide resection
with subsequent microsurgically revascularised bone re-
construction. Over time, our therapy regimen changed from
mainly conservative at the beginning to preferably minim-
ally invasive surgery for complete remission. This change
was made with the aim of achieving a higher success rate
without limitation on the quality of life. If possible, a drug
holiday of about 3 to 6 months was taken from before sur-
gical intervention until complete healing of the oral mucosa
about 2 weeks after surgery.
All patients were followed up regularly, with the frequency
depending on their individual situation and location.
In 2/112 patients, histological examination detected malig-
nant cells, whereas clinical and imaging findings showed
typical signs of BRONJ. These two patients were excluded
from statistical analysis.
All patients signed an informed consent form prior to the
analysis of their data, which were initially obtained for
medical purposes. The study design satisfied the Declara-
tion of Helsinki guidelines and ethical principles for med-
ical research involving human subjects.
Since the discovery of BRONJ in 2003, we have conducted
a continuous literature search including the regular screen-
ing of current literature databases such as MEDLINE,
EMBASE, and the Cochrane Library for key words such
as “bisphosphonate”, “osteonecrosis of the jaw”, “osteo-
porosis”, and “antiresorptive treatment”. Articles in Eng-
lish, German, Italian, and French were evaluated. Addition-
al references of interest identified in the reference lists of
relevant articles were also added to the library. The “lib-
rary” was grouped into different sections such as aetiology,
diagnostics, treatment, oral bisphosphonates, guidelines,
and prevention, and each section contained different sub-
groups. Many different kinds of articles, such as case
series, animal studies, case reports, original articles, and re-
views, were added to the library. Thus, a constant literature
update of current knowledge could be ensured.
Results
In total, 110 patients (33 [30%] men, 77 [70%]) women)
were referred to the osteonecrosis clinic for BP-induced os-
Figure 1
Display of underlying malignant disease and gender distribution of
all patients (m = male; f = female).
Figure 2
Female patient with osteoporosis and BRONJ of the left posterior
maxilla including the maxillary sinus. The clinical picture shows
exposed bone with signs of infection of the surrounding and pus
discharge.
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teopathology of the jaw during 2003–2010. Eighty-three
patients were treated with bone resorption inhibitors due to
underlying malignant disease and 27 patients were treated
for osteoporosis. The mean age of all patients was 67 years;
in patients with osteoporosis, the mean age was 72 years,
whereas in patients with malignant disease, the average age
was 7 years younger (mean, 65 years).
Underlying disease
Of the patients with underlying malignant disease, 46% (n
= 38) were treated for metastasised breast cancer, 30% (n =
25) had multiple myeloma, 12% (n = 10) had prostate can-
cer, and 12% (n = 10) were treated for other malignant dis-
eases, such as lymphoma, carcinoma of the bladder, lung
A
B
Figure 3
A Female patient with BRONJ of the right anterior mandible
associated with periapical infection of the canine. The clinical
picture shows no exposed bone, but signs of infection of the
surrounding soft tissue and periodontal pus discharge.
B The same patient as figure 3A. Intraoperative view shows clearly
the necrotic bone area in contrast to the vital bone in the left
mandible. The necrotic area is surrounded from granulation tissue.
Bone appears green-greyish.
Figure 4
Same patient as figure 2 shows the situation after surgical
treatment of BRONJ with complete remission without any remaining
dehiscence of the soft tissue.
carcinoma, carcinoma of the thyroid, melanoma, and renal
cell carcinoma. All patients without underlying malignant
disease were treated for osteoporosis (fig. 1).
Medication
Most patients with malignancies received zoledronic acid
(93%), followed by pamidronate (table 1). Some patients
were treated with BPs other than intravenous BPs (ibandro-
nate, n = 5; alendronate, n = 2), and one patient received
the RANKL inhibitor denosumab with no previous or sub-
sequent BP therapy. In 15 (18%) patients, the drug regimen
was changed during the duration of the underlying disease
because of side effects, the onset of osteonecrosis, or the
availability of the more potent BP, zoledronic acid. The
mean duration of bone resorption-inhibition therapy until
the onset of osteopathology was 34 months in patients with
underlying malignant disease and 24 months for the patient
with denosumab treatment. Most patients with underlying
malignant disease were treated with additional chemothera-
peutic agents, and in seven patients, specific data were
missing. Seven female patients with breast cancer and one
male patient with prostate cancer did not receive chemo-
therapy but only hormone therapy.
Most patients with non-malignant underlying disease were
treated with alendronate (44%) or ibandronate (41%). At
least six patients received the intravenous agents pamidro-
nate or zoledronic acid. In four patients, therapy was
changed to annual doses of zoledronic acid (Aclasta®; No-
vartis Pharma, Switzerland, Bern). One patient was treated
with risedronate. The drug regimens of seven (26%) pa-
tients were changed.
The mean duration of BP therapy until the onset of osteo-
pathology was 42 months in patients with osteoporosis.
Of all patients with osteoporosis, five received additional
systemic corticosteroids. Of those patients, one received
additional immunosuppressive therapy due to previous ren-
al transplantation.
Localisation
The mandible was affected in 74% of patients and the max-
illa was affected in 28%. The molar region was the most
common site of osteonecrosis; about 78% of mandibular
lesions and 77% of maxillary lesions affected this region.
Osteopathology was less common in the frontal areas of
the maxilla and mandible; these regions were affected in
only 17% (n = 19) of all patients, and most of those lesions
were large and originated in the premolar or molar region
(table 1).
Local factors
In all patients, a local incident was correlated with the area
of subsequent osteopathology occurrence, meaning that the
study sample included no case of spontaneous occurrence.
In some patients, more than one factor was correlated with
more than one area of subsequent bone necrosis. In most
(64%) patients, extractions were performed in the area of
bone pathology, mostly due to previous periapical infection
or massive loosening due to periodontal disease. Other loc-
al incidents were the insertion of screwed implants, peri-
odontal disease, periapical foci, or pressure ulcers due to
Original article Swiss Med Wkly. 2012;142:w13605
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a poorly fitting prosthesis. Descriptive statistics of patients
are displayed in table 1.
Clinical presentation
The majority (75%) of patients presented with pain as their
major concern. All patients showed signs of infection in the
area of the affected jaw, which involved pus discharge, abs-
cess formation, or inflamed surrounding soft tissue (fig. 2).
Exposed bone was observed in only 74% of patients; 23%
of patients presented with a fistula, but without clinically
evident exposed bone (only radiologically evident affected
bone) (fig. 3a and b). All of those patients except one were
treated surgically; therefore, the diagnosis of osteopatho-
logy of the jaw was also affirmed clinically.
Histological findings
Histological examination of bone specimens was per-
formed in 66 patients. In two patients, tumour cells of the
underlying disease (breast cancer, n = 1; multiple myeloma,
n = 1) were found; thus, their diagnoses were revised and
they were excluded from the study. The analysis thus ex-
amined histological data from 64 patients.
Dead bone (acellular bone without osteocytes, osteoclasts,
or osteoblasts) with signs of acute and chronic inflamma-
tion and bacterial colonisation was found in all patients.
Plaques of Actinomyces were specifically described in 46/
64 (72%) histological analyses of osteopathology due to
bone resorption inhibitors, whereas the remaining cases
were not specifically tested for the presence of Actinomy-
ces.
Treatment
About ⅔ (n = 19) of patients in the osteoporosis group were
treated surgically. In the remaining eight patients, surgery
was either unnecessary due to secondary healing after local
revision of the affected bone, or refused by the patient.
Forty-five (53%) patients with underlying malignant dis-
ease were treated surgically, and the others were treated
conservatively due to poor general health status or refusal
of surgical treatment.
Table 1: Descriptive Statistics of study cohort, displaying gender, type of bisphosphonate localisation of osteopathology, local risk factor, clinical picture and type of
treatment and outcome, respectively for patients with underlying malignant disease and osteoporosis.
Underlying malignant disease
n (%)
Osteoporosis
n (%)
Total
n (%)
Total n (%) 83 (75) 27 (25) 110
Sex f 53 (64) 24 (89) 77 (70)
m 30 (36) 3 (11) 33 (30)
Mean age 65 72 67
Bisphosphonate1 Zoledronic acid 77 (93) 3* 80 (73)
Pamidronate 13 5 18
Alendronate 2 12 (44) 14
Ibandronate 5 11 (41) 16
Others** 1 2 6
Localisation1 Mandible 62 (75) 19 (70) 81 (74)
Molars 48 15 63 (57)
Premolars 28 9 37
Front 10 4 14
Maxilla 23 (28) 8 (30) 31 (28)
Molars 18 6 24 (22)
Premolars 8 5 13
Front 4 1 5
local risk factor1 Extraction 55 (66) 15 (56) 70 (64)
Prosthesis 11 7 18
Implantation 9 6 15
Perioodontal disease 10 1 11
Other *** 18 4 22
Clinical presentation1 n (%) Pain 62 21 83
Pus 49 14 63
Abscess 23 5 28
Paresthesia 19 2 21
Exposed bone 62 19 81 (74)
Fistula 19 6 25
Involvmemnt of sinus 11 3 14
Signs of infection 83 27 110
Treatment n (%) Surgery 45 (54) 19 (70) 64 (58)
Complete remission 32 (71) 18 (95) 50 (78)
Partial remission 7 1 8
No improvement 6 0 6
* Three patients received zoledronic acid 1/year and the other monthly.
** Others included: Denosumab, risedronate.
*** Other included: periapical infection, tori mandibulares, root canal treatment.
1 Patients may belong to more than one group.
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Of the surgically treated patients with osteoporosis, 95%
showed complete remission (fig. 4), and one female patient
showed partial remission with a small area of remaining ex-
posed bone, but had no complaint. Complete remission was
achieved in 71% of surgically treated patients with under-
lying malignant disease; partial remission was achieved in
seven patients, and six patients showed no improvement at
the surgically treated site.
Only nine patients in the conservative treatment group
showed some kind of decrease in the size of exposed bone,
mostly due to several minor local revisions in the outpatient
setting. All of them had improvement of symptoms due to
systemic anti-infectious treatment, but complete remission
was only achieved in three patients.
Discussion
ONJ in association with BP therapy is currently a recog-
nised disease, but much about this condition remains un-
clear. Currently, the definition and classification of the
AAOMS, which was introduced in 2007 and updated in
2009, is widely accepted. Exposed bone is one of the three
decisive points for the clinical confirmation of the specific
diagnosis.
In this study, we analysed data of 112 patients with os-
teopathology associated with bone resorption–inhibiting
drugs. All patients showed local risk factors in addition to
therapy with bone resorption inhibitors, and a majority of
patients showed impairment of the immune system due to
the underlying disease and immunosuppressive therapies.
Histological analyses of affected bone showed signs of in-
flammation in each specimen, with the presence of Actino-
myces in a noticeable number of specimens. Surgical ther-
apy showed excellent results, especially in patients with
osteoporosis. Interestingly, only 74% of patients actually
showed exposed bone, as required for a diagnosis of
BRONJ according to the AAOMS criteria. This discrep-
ancy is another example of the need for revision of the
current definition and classification of this disease, as pro-
posed by other authors [5]. In the following section, we
present a structured overview of our results and updated
knowledge about osteopathology of the jaw in association
with bone resorption–inhibiting therapy.
Epidemiology
It has been shown in the last several years that the incid-
ence of ONJ associated with BP therapy is higher in pa-
tients with cancer than in those with a non-malignant un-
derlying disease. Several studies have found the prevalence
of BRONJ to be about 0–18.3% in patients with various
types of underlying malignant disease [9–11]. The preval-
ence in patients who received BP therapy for osteoporos-
is or other non-malignant disease with pathologically high
bone resorption seems to be much lower (0.01–0.21%, de-
pending on the duration of BP therapy); post-marketing
data suggest an incidence of 1 per 100 000 persons per year
[12]. However, few studies have investigated a representat-
ive number of such patients [13, 14].
In this study, 75% of patients received BP treatment due
to an underlying malignant disease and 25% received these
drugs due to osteoporosis, an uncommonly high rate in
comparison with other reported studies. In a summary-ana-
lysis of 2400 previously published BRONJ cases, Filleul et
al. [15] found that 89% of all patients were treated for ma-
lignant disease and 11% for underlying osteoporosis, sim-
ilar to the findings of other studies [16, 17]. The reason for
the high rate of patients with BRONJ and osteoporosis in
our sample may be an interesting topic for further studies.
Risk factors and pathogenesis
Although the patho-aetiological process of BRONJ re-
mains incompletely understood, it seems to be multifactori-
al. Apart from possibly associated new risk factors, such as
genetic polymorphism [18], several major risk factors have
been identified and established in the literature. They can
be divided into the following categories:
1. Therapy with bone resorption-inhibiting drugs,
2. General factors, and
3. Local factors.
As shown over time, BP type, cumulative dose, and treat-
ment duration are correlated with the risk of BRONJ de-
velopment [9]. Several authors have shown an increase in
the incidence of BRONJ in correlation with the duration of
BP treatment or number of doses administered [15, 19, 20],
demonstrating the need to revise the duration and schemes
of BP therapy in patients with underlying malignant dis-
ease and osteoporosis. Nevertheless, verifying a correlation
between a specific BP and the risk of BRONJ development
is somewhat difficult because the general factors such as
immunosuppression are often strongly associated with a
high dosage and a high-potency drug regimen and are also
believed to be risk factors. In this study, the majority of pa-
tients were treated monthly with an intravenous administra-
tion of zoledronic acid.
One important new aspect of our developing understanding
of BRONJ is the expansion of causative drugs, which in-
clude other bone resorption inhibitors. Recently, the
RANKL inhibitor Prolia® and Xgeva® (denosumab; Am-
gen, Zug, Switzerland) were introduced in studies of ther-
apy for skeletal-related tumour events and compared with
zoledronic acid therapy [8, 21]. In those studies, BRONJ
also occurred in patients receiving denosumab treatment.
For example, Saad et al. [22] found a BRONJ incidence
of 1.8% in patients receiving denosumab treatment, versus
1.3% in patients receiving zoledronic acid, in three blinded
phase III trials. In our patient group, denosumab therapy
was the causative agent in one male patient [23, 24]. The
appearance of similar osteopathology with denosumab
raises the question of whether the actual risk factor might
be the degree of osteoclast inhibition, with subsequent de-
creased remodelling and defence abilities in the bone.
Thus, the term BRONJ is, strictly speaking, obsolete and
the condition should be renamed (e.g., osteopathology of
the jaw associated with bone resorption inhibitors).
A few studies have investigated the influence of drugs oth-
er than BPs on the risk of BRONJ development. Most stud-
ies found no significant correlation between the incidence
of BRONJ and the treatment of underlying malignancies
with other drugs, such as tamoxifen, melphalan, and an-
thracyclines [25]. Further, the role of glucocorticosteroids
as a potential additional risk factor remains unclear [10].
Original article Swiss Med Wkly. 2012;142:w13605
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Generally, therapy with bone resorption inhibitors is
closely correlated with some general factors that have been
found to have an influence, such as immunosuppression,
regardless of whether it is due to the underlying disease or
to medication. Patients with malignant underlying diseases,
especially multiple myeloma, are at highest risk of devel-
oping ONJ. Usually, the immune defences of those patients
are highly impaired by the disease and by various therapies.
Some authors, such as Subramaniam et al. [26], have ar-
gued that the suppression of osteoblast function, depend-
ing on the underlying disease (e.g., in patients with mul-
tiple myeloma), is an important general risk factor for the
development of ONJ [26]. Another general risk factor un-
der current discussion is the age of the patient [19].
In addition to systemic and general factors, some local
events are clearly linked to the occurrence of osteopath-
ology. Similar to our 2006 study [1], each patient in our
present sample had a local event in the same area as sub-
sequent bone necrosis. Most (64%) patients had previous
dental extractions, but periodontal disease, pressure ulcers,
root canal treatment, implant insertion, and periapical in-
fections were also evaluated as local risk factors. Dental
extractions were clearly shown to increase the risk of ONJ
development. Vahtsevanos et al. [19] reported an
18–33-fold higher risk of ONJ development in patients
with a dental extraction history, and other authors have
confirmed this finding. In the same study, Vahtsevanos et
al. [19] reported a two-fold higher risk in patients wear-
ing dentures, supposedly due to the direct negative in-
fluence of BP on mucosal healing. Implant insertion re-
mains under discussion as a local risk factor, especially in
patients with osteoporosis. To date, few reports have de-
scribed patients with BRONJ in association with dental im-
plant placement. Lazarovici et al. [27] for example, presen-
ted a case series in which implant insertion was a local
triggering factor in 27/145 (18.6%) patients with BRONJ,
regardless of whether the patients had a malignant disease
or osteoporosis. In this study, dental implant insertion was
a local triggering factor for the development of subsequent
osteopathology in 15 (14%) patients. According to other
studies [28], not only implant insertion, but also peri-im-
plant communication between the implant and the jawbone
seems to be a risk factor [29]. Several studies or case series
have shown that ONJ in areas of previously inserted im-
plants developed chronologically independently from the
insertion procedure [28, 30].
In contrast to most reports, no spontaneous lesion was
found in this study. Typical reported rates of potential spon-
taneous lesions have ranged from 10–25% of cases [15, 16,
31]; however, in our experience, the presence of spontan-
eous lesions is somewhat questionable and would be an in-
teresting topic for further analysis. Despite the experience
gained during the last years, the hypothesised major impact
of a potential local factor involving pathogenic invasion of
the bone, and the possible infection of a bone with inhibited
remodelling potential due to BP therapy, remains unproven
[1]. Local injury with pathogenic invasion or primary in-
fection of bone with disturbed remodelling due to a bone
resorption inhibitor may be associated with preceding or
subsequent bone necrosis in the region. People with restric-
ted systemic immune defences, such as patients with mul-
tiple myeloma, are at higher risk than patients with healthy
immune system.
In an interesting study, Saia et al. [32] tried to establish pre-
dictors for the development of BRONJ after tooth extrac-
tion. They tested several variables in 60 patients who re-
ceived BP therapy and necessary extraction therapy: age,
gender, malignancy, and baseline osteomyelitis (histologic-
ally detected inflammation of alveolar bone at the time
of extraction). Five of the 60 patients developed BRONJ
after tooth extraction; bone biopsies of these five patients
showed baseline osteomyelitis. Thus, the role of oral patho-
gens and infection is believed to be an important factor in
the pathogenesis of this disease. This hypothesis might be
supported by the fact that all patients in the present study
showed clinical signs of infection, such as granulation tis-
sue or inflammation of surrounding soft tissue. Pus dis-
charge was found in half of the patients, abscess formation
was present in one-quarter of patients, and maxillary sinus
infection was clinically evident in 13%. Of all 112 patients,
74% presented with pain. Half of the patients underwent
biopsies of the affected bone; all showed signs of infec-
tion and Actinomyces was present in 70%. It remains un-
clear whether the presence of Actinomyces indicates an in-
vasive infection or simple colonisation of the bone [33, 34].
Several study findings have supported the hypothesis of in-
flammation as a major factor in the aetiological process.
For example, Lesclous et al. [35] analysed specimens from
30 patients with BRONJ, and found a correlation between
the severity of bone marrow inflammation and the “clinic-
al extent” of BRONJ; they concluded that BRONJ might
develop as a sequential event, with bacterial invasion as a
major factor. Kassolis et al. [36] presented another inter-
esting finding in 2010. They examined bone from eden-
tulous alveolar ridges histologically and found non-viable
bone in 35% and bone with signs of osteomyelitis in 15%
of all cases, respectively. With this finding, they suggested
that “subclinical infected areas and areas with non-viable
bone” might represent high-risk areas for the development
of BRONJ.
Diagnosis
During the last 7 years, many different diagnostic methods
have been evaluated. Still, careful investigation of the pa-
tient’s medical history and clinical examination are the
most important steps in the decision-making process. The
predictive usefulness of specific diagnostic measures, such
as the carboxy-terminal collagen crosslink (CTX) level, re-
mains debated; to date, no evidence-based data concerning
risk prediction are available [37–39].
Imaging is necessary for the analysis of necrotic lesion size
and treatment planning, especially in those patients with
non-exposed bone [40, 41], anyhow 26% of patients in
this study. Several non-specific radiographic findings have
been identified, such as sclerotic changes, periosteal reac-
tion, sequestra, and areas of lucency [42]. CT, cone-beam
CT, or MRI is needed to demonstrate the lesions and their
extent [42–45]. A plain radiograph is a useful basic tool for
the identification of possible current dental infections and
necessary dental therapy, but is not sufficient for the iden-
tification of the affected jawbone [42]. O’Ryan et al. [46]
demonstrated the role of bone scintigraphy as an early in-
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dicator, showing tracer uptake in 66% of 59 patients before
clinical evidence of jaw lesions. Unfortunately, they did not
correlate this information with dental history. Moreover,
preventive diagnostic imaging would be too expensive to
use in all patients receiving BP therapy and the benefits are
questionable. Should a lesion been treated without clinical
evidence? [47, 48]
Another important diagnostic measure is the histological
analysis of the affected site to exclude tumor invasion.
In this study, we saw malignant histological specimens in
two patients, although clinical and radiological diagnostic
measures clearly suggested ONJ.
Therapy
ONJ treatment has changed markedly since 2003. Cur-
rently, most “therapy-resistant” jaw pathologies can be
controlled surgically. Three main pillar strategies remain:
(1) treatment of the infection, (2) local rehabilitation of the
affected bone and soft tissue, and (3) necessary prevent-
ative measures. Early guidelines recommended the most
conservative treatment possible [4, 49–51]. Therapy res-
istance with dehiscence of the surgical incision, progres-
sion of the infection, and bone destruction stoked fears of
surgical intervention in these patients [52]. As a conse-
quence, many practitioners looked for alternative, nonin-
vasive treatment options for this disease, such as hyper-
baric oxygen or low-level laser therapy [53, 54]. However,
exclusively conservative treatment of patients with ONJ
in our patient population was shown to increase the fre-
quency of acute infectious episodes and therefore the fre-
quency and duration of antibiotic treatment. Additionally,
the quality of life in patients with infected exposed bone
is often highly restricted in terms of pain, halitosis, an-
tibiotic side effects, and the need for numerous visits to
the dentist for local rinsing of the affected jaw. Further-
more, surgical therapy has been shown to be more effective
than previously suggested [55]. Several authors have repor-
ted successful surgical treatment of ONJ lesions with vary-
ing levels of radical surgery and differing protocols for BP
therapy (interruption or continuation) [56–58]. Increased
experience has revealed that surgical therapy as minor as
possible, but with total excision of all necrotic and infec-
ted bone areas, after 3–6 months of BP discontinuation has
led to a high rate of complete remission in these patients. In
this study, 58% of all patients were treated surgically and
the frequency of surgical therapy increased over the study
period. Complete remission was achieved in 78% of all pa-
tients, whereas this success rate was higher (95%) in pa-
tients with osteoporosis. Given the previously mentioned
association of BRONJ with infection, all patients were ad-
ditionally given systemic anti-infective therapy with anti-
biotics; this treatment resolved symptoms, especially pain,
in all patients. Apart from surgical treatment, preventative
measures, as recommended in earlier studies [1], remain of
the utmost importance and have been shown to have bene-
ficial effect [59, 60].
This study shows an ongoing learning effect in all aspects
of dealing with osteopathology of the jaws in patients tak-
ing bone-resorption inhibitors. After almost 8 years of
gathering knowledge in dealing with this disease, we hy-
pothesise that this disease is a kind of osteomyelitis in
a specifically pre-treated bone. However, evidence-based
data are still lacking; we have only clinical findings. One
strength of this study was that all patients were treated and
followed up in the special clinic. Therefore, only a lim-
ited number of practitioners collected patient data. This art-
icle provided an overview about BRONJ. However, out-
lining all the data in one article was difficult, and not all
information could be given, which is the major limitation
of this article. Nevertheless, the most important facts for
specialists dealing with patients taking bone-resorption in-
hibitors, and especially the information about the signific-
ance of local risk factors and currently successful treatment
options, were provided.
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Figures (large format)
Figure 1
Display of underlying malignant disease and gender distribution of all patients (m = male; f = female).
Figure 2
Female patient with osteoporosis and BRONJ of the left posterior maxilla including the maxillary sinus. The clinical picture shows exposed bone
with signs of infection of the surrounding and pus discharge.
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AB
Figure 3
A Female patient with BRONJ of the right anterior mandible associated with periapical infection of the canine. The clinical picture shows no
exposed bone, but signs of infection of the surrounding soft tissue and periodontal pus discharge.
B The same patient as figure 3A. Intraoperative view shows clearly the necrotic bone area in contrast to the vital bone in the left mandible. The
necrotic area is surrounded from granulation tissue. Bone appears green-greyish.
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Figure 4
Same patient as figure 2 shows the situation after surgical treatment of BRONJ with complete remission without any remaining dehiscence of
the soft tissue.
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